Exogenus’ core technology makes use of Extracellular Vesicles released by Umbilical Cord Blood cells, purified by a proprietary production process, and characterized using standardized methods implemented at our company.

Umbilical Cord Blood:

A Privileged Raw Material

Rather than being seen as medical waste, umbilical cord blood (UCB) has received great interest in the past three decades for its use as a medicinal product. Since the first UCB transplant in the late 1980s‚ this cellular therapy has been used mostly for the treatment of leukemias, as well as other malignant and non-malignant disorders1. Data from 2014 shows that over 40.000 transplants have been performed in Europe1, a number that is estimated to continue growing as UCB banking increases. It is worth noting that cryopreservation of UCB can remain therapeutically valuable for at least 20 years, without significant changes to its hematopoietic stem cell viability or engrafting capability2.

The interest around UCB lies not only on its richness in hematopoietic stem and progenitor cells3, but also on its potential usefulness for regenerative medicine and immune modulation4. Several clinical trials are currently investigating the use of UCB for a number of diseases, including type I diabetes, stroke and viral infections5.

Exogenus Therapeutics endorses the potential of UCB as a raw material for the treatment of regenerative and immunological disorders, and is actively contributing to advance the field of UCB-derived medicinal products.


Passweg, J. R. et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants  annually. Bone Marrow Transplant. 51, 786–792 (2016).

Broxmeyer, H. E. et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells,  and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood 117, 4773–4777 (2011).


Ballen, K. K., Gluckman, E. & Broxmeyer, H. E. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 122, 491–498 (2013).

Damien, P. & Allan, D. S. Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood–Derived Cells. Biol. Blood Marrow Transplant. 21, 1545–1554 (2015).

Kindwall-Keller, T. L. & Ballen, K. K. Umbilical cord blood: The promise and the uncertainty. Stem Cells Transl. Med. 9, 1153–1162 (2020).